{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:25:34Z","timestamp":1792070734764,"version":"4.4.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Primary aldosteronism (PA) is a potentially curable form of secondary hypertension caused by excessive renin-independent aldosterone secretion, leading to increased target organ damage and cardiovascular morbidity and mortality. The diagnosis of PA requires measuring renin and aldosterone to calculate the aldosterone-to-renin ratio, followed by confirmatory tests to demonstrate renin-independent aldosterone secretion and\/or PA subtype differentiation. Various antihypertensive drug classes interfere with the renin-angiotensin-aldosterone axis and hence evaluation for PA should ideally be performed off-drugs. This is, however, often precluded by the risks related to suboptimal control of blood pressure and serum potassium level in the evaluation period. In the present review, we summarized the evidence regarding the effect of various antihypertensive drug classes on biochemical testing for PA, and critically appraised the issue whether and which antihypertensive medications should be withdrawn or, conversely, might be continued in patients evaluated for PA. The least interfering drugs are calcium antagonists, alpha-blockers, hydralazine, and possibly moxonidine. If necessary, the testing may also be attempted during treatment with beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but renin and aldosterone measurements must be interpreted in the context of known effects of these drugs on these parameters. Views are evolving on the feasibility of testing during treatment with mineralocorticoid receptor antagonists, as these drugs are now increasingly considered acceptable in specific patient subsets, particularly in those with severe hypokalemia and\/or poor blood pressure control on alternative treatment.<\/jats:p>","DOI":"10.3389\/fphar.2021.684111","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T10:15:08Z","timestamp":1620900908000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism"],"prefix":"10.3389","volume":"12","author":[{"given":"Piotr","family":"J\u0119drusik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Symonides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Gaciong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1210\/jc.2010-0225","article-title":"Effect of Atenolol on Aldosterone\/renin Ratio Calculated by Both Plasma Renin Activity and Direct Renin Concentration in Healthy Male Volunteers","volume":"95","author":"Ahmed","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2016-3821","article-title":"Effect of Moxonidine on the Aldosterone\/Renin Ratio in Healthy Male Volunteers","volume":"102","author":"Ahmed","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of Renin-independent Aldosteronism in Normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"key":"B4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1309\/8EXC-CM6Y-R1TH-UBAF","article-title":"Toward Complete and Accurate Reporting of Studies of Diagnostic Accuracy","volume":"119","author":"Bossuyt","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The Unrecognized Prevalence of Primary Aldosteronism","volume":"173","author":"Brown","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/cen.12882","article-title":"\u03b2-Blocker Withdrawal Is Preferable for Accurate Interpretation of the Aldosterone-Renin Ratio in Chronically Treated Hypertension","volume":"84","author":"Browne","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJM197212142872401","article-title":"Propranolol Inhibition of Renin Secretion","volume":"287","author":"B\u00fchler","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1708","DOI":"10.1210\/clinem\/dgaa974","article-title":"Development of a Prediction Score to Avoid Confirmatory Testing in Patients with Suspected Primary Aldosteronism","volume":"106","author":"Burrello","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of Primary Hyperaldosteronism in Resistant Hypertension: a Retrospective Observational Study","volume":"371","author":"Douma","year":"2008","journal-title":"The Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1210\/jcem.82.2.374810.1210\/jc.82.2.457","article-title":"Effects of Nifedipine Treatment on the Renin-Angiotensin-Aldosterone axis","volume":"82","author":"Fiad","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11154-011-9163-7","article-title":"Commentary on the Endocrine Society Practice Guidelines: Consequences of Adjustment of Antihypertensive Medication in Screening of Primary Aldosteronism","volume":"12","author":"Fischer","year":"2011","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/s0272-6386(01)80117-7","article-title":"Screening for Primary Aldosteronism Without Discontinuing Hypertensive Medications: Plasma Aldosterone-Renin Ratio","volume":"37","author":"Gallay","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/07435809209035402","article-title":"Renal and Adrenal Responsiveness to Angiotensin II: Influence of Beta Adrenergic Blockade","volume":"18","author":"Gordon","year":"1992","journal-title":"Endocr. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/HJH.0000000000000775","article-title":"A Cross-Sectional Study of the Effects of \u03b2-blocker Therapy on the Interpretation of the Aldosterone\/renin Ratio","volume":"34","author":"Griffin","year":"2016","journal-title":"J. Hypertens."},{"key":"B18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1210\/jcem-57-2-339","article-title":"Effects of Intravenous and Oral Verapamil Upon Pressor and Adrenal Steroidogenic Responses in Normal Man","volume":"57","author":"Guthrie","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1210\/jc.2014-2788","article-title":"Outcome of Adrenal Vein Sampling Performed During Concurrent Mineralocorticoid Receptor Antagonist Therapy","volume":"99","author":"Haase","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/archinte.141.12.1589","article-title":"A Screening Test to Identify Aldosterone-Producing Adenoma by Measuring Plasma Renin Activity. Results in Hypertensive Patients","volume":"141","author":"Hiramatsu","year":"1981","journal-title":"Arch. Intern. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MNH.0000000000000702","article-title":"How Common Is Primary Aldosteronism?","volume":"30","author":"Hundemer","year":"2021","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0002-9343(87)90160-4","article-title":"Vasodilators and Regression of Left Ventricular Hypertrophy","volume":"82","author":"Leenen","year":"1987","journal-title":"Am. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1210\/jcem-57-5-892","article-title":"Single Dose Captopril as a Diagnostic Test for Primary Aldosteronism","volume":"57","author":"Lyons","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005574","article-title":"Quantitative Value of Aldosterone\u2010Renin Ratio for Detection of Aldosterone\u2010Producing Adenoma: The Aldosterone\u2010Renin Ratio for Primary Aldosteronism (AQUARR) Study","volume":"6","author":"Maiolino","year":"2017","journal-title":"Jaha"},{"key":"B26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.0954-6820.1981.tb11587.x","article-title":"Prolonged Clonidine Treatment: Catecholamines, Renin Activity and Aldosterone Following Exercise in Hypertensives","volume":"209","author":"Manhem","year":"1981","journal-title":"Acta Med. Scand."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular Events and Target Organ Damage in Primary Aldosteronism Compared with Essential Hypertension: a Systematic Review and Meta-Analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.hyp.0000038478.59760.41","article-title":"Drug Effects on Aldosterone\/plasma Renin Activity Ratio in Primary Aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/jc.2018-01299","article-title":"Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism","volume":"104","author":"Nanba","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1507\/endocrj.ej11-0133","article-title":"Guidelines for the Diagnosis and Treatment of Primary Aldosteronism -The Japan Endocrine Society 2009-","volume":"58","author":"Nishikawa","year":"2011","journal-title":"Endocr. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0002-9149(91)90438-q","article-title":"Effects of Doxazosin on Blood Pressure, Renin-Angiotensin-Aldosterone and Urinary Kallikrein","volume":"67","author":"Oliveros-Palacios","year":"1991","journal-title":"Am. J. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1210\/js.2019-00145","article-title":"Diagnostic Accuracy of the Aldosterone-To-Active Renin Ratio for Detecting Primary Aldosteronism","volume":"3","author":"Pilz","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.ijchy.2020.100029","article-title":"The 2020 Italian Society of Arterial Hypertension (SIIA) Practical Guidelines for the Management of Primary Aldosteronism","volume":"5","author":"Rossi","year":"","journal-title":"Int. J. Cardiol. Hypertens."},{"key":"B35","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40292-020-00415-9","article-title":"Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension","volume":"27","author":"Rossi","year":"","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1210\/clinem\/dgaa080","article-title":"Effects of Mineralocorticoid and AT1 Receptor Antagonism on the Aldosterone-Renin Ratio in Primary Aldosteronism-The EMIRA Study","volume":"105","author":"Rossi","year":"","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.jacc.2019.09.057","article-title":"Primary Aldosteronism","volume":"74","author":"Rossi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/HYPERTENSIONAHA.109.139832","article-title":"Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism","volume":"55","author":"Rossi","year":"2010","journal-title":"Hypertension"},{"key":"B39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1530\/eje.1.02164","article-title":"Confirmatory Testing in Normokalaemic Primary Aldosteronism: the Value of the Saline Infusion Test and Urinary Aldosterone Metabolites","volume":"154","author":"Schirpenbach","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1046\/j.1365-2265.2002.01613.x","article-title":"Influence of Antihypertensive Medication on Aldosterone and Renin Concentration in the Differential Diagnosis of Essential Hypertension and Primary Aldosteronism","volume":"57","author":"Seifarth","year":"2002","journal-title":"Clin. Endocrinol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"86S","DOI":"10.1592\/phco.19.7.86s.30949","article-title":"The Renal Profile of Eprosartan","volume":"19","author":"Sica","year":"1999","journal-title":"Pharmacotherapy"},{"key":"B42","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1530\/EJE-11-0914","article-title":"Confirmatory Testing in Primary Aldosteronism: Extensive Medication Switching Is Not Needed in All Patients","volume":"166","author":"Solar","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.4158\/EP-2020-0277","article-title":"Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism","volume":"26","author":"Tezuka","year":"2020","journal-title":"Endocr. Pract."},{"key":"B44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1440-1681.1987.tb00967.x","article-title":"Acute Haemodynamic and Hormonal Effects of Oral Doxazosin in Normal Subjects","volume":"14","author":"Whitworth","year":"1987","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary Aldosteronism in Patients in China with Recently Detected Hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","article-title":"Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension"},{"key":"B47","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3109\/08037059609079679","article-title":"Malignant Hypertension in Association with Primary Aldosteronism","volume":"5","author":"Zarifis","year":"1996","journal-title":"Blood Press"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.684111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T10:15:10Z","timestamp":1620900910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.684111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":47,"alternative-id":["10.3389\/fphar.2021.684111"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.684111","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"article-number":"684111"}}